CD4 and glioblastoma: The importance of CD4+ T cells in driving antitumour responses are highlighted by showing that melanoma-derived neoepitopes are recognized by CD4+ T cells16, and neoantigen vaccinations in melanoma and glioblastoma primarily activate CD4+ T cells17–19.